
Chondroitin Sulfate
Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific patterns. Depending on the predominating disaccharide unit, it will present different biological activities. Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe. — DrugBank
- IUPAC-Name
- (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
- Summenformel
- C13H21NO15S
- Molekulargewicht
- 463.37 g/mol
- Exakte Masse
- 463.06319014 Da
- XLogP3
- -4,8
- Topologische polare Oberfläche
- 267,0 Ų
- Wasserstoffbrücken-Donoren
- 8
- Wasserstoffbrücken-Akzeptoren
- 15
- Kovalente Einheiten
- 1
- Definierte Stereozentren
- 10
Auch bekannt als
16 weitere gemeldete Namen
Kennungen in externen Datenbanken
- ChEMBL:CHEMBL5266347
- EPA DTXSID:DTXSID601017238
- PubMed:5601
Am 2026-08-31 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.